Clinical trials: Major Cardiovascular Event
Obesity
Effects of OAGB and DJB-SG on 10-year and Lifetime Risks of MACE
Metabolic bariatric surgery (MBS) has demonstrated its efficacy in achieving sustainable weight loss and alleviating associated comorbidities.
- Trial name
- NCT06254339
- Testing
- OAGB, DJB-SG
- Volunteers
- 830 people
- Sponsor
- National Defense Medical Center, Taiwan
Diabetes, Renal Failure , Chronic
Implementation Trial In patieNts With rEnal failuRe and diAbetes for Major Adverse reNal and Cardiovascular Events
The goal of this clinical study is to establish if the use of public health-related messages, designed and disseminated to a targeted population, will result in tangible improvements in patient outcomes and healthcare practices.
- Trial name
- ITINERANCE (NCT07634718)
- Testing
- Health-related messages
- Where
- France
- Volunteers
- 125,000 people
- Sponsor
- Nantes University Hospital
Stable Chronic Angina
Ticagrelor vs. Clopidogrel in Post PCI Patients
Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg…
- Trial name
- NCT05858918
- Testing
- Clopidogrel, Ticagrelor
- Where
- Iran
- Volunteers
- 476 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
HIV - Human Immunodeficiency Virus
Coronary Artery Calcium Score in HIV Mexican Population (The CACsHIVMex Study)
The risk of atherosclerotic cardiovascular disease is increased in people with HIV infection, including young patients and those with few traditional cardiovascular risk factors.
- Trial name
- CACsHIVMex (NCT07662161)
- Testing
- Simple coronary CT scan
- Where
- Mexico
- Volunteers
- 384 people
- Sponsor
- Instituto Mexicano del Seguro Social
Peripheral Arterial Disease, Myocardial Injury
Cardiovascular Risk in Peripheral Artery Disease Patients Undergoing Endovascular Revascularisation
This study will investigate heart-related complications in patients with peripheral arterial disease (PAD) undergoing endovascular revascularization procedures to improve blood flow in the legs.
- Conditions
- Peripheral Arterial Disease, Myocardial Injury, Troponin, NT-proBNP
- Trial name
- RISK (NCT07599540)
- Where
- Slovenia
- Volunteers
- 500 people
- Sponsor
- University Medical Centre Ljubljana
Coronary Artery Disease, Coronary Artery Bypass Grafting
CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial
The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Coronary Computed Tomography Angiography, Coronary Angiography (CAG)
- Trial name
- CtaCAB (NCT07769008)
- Testing
- CCTA-based CABG, CAG-based CABG
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Ruijin Hospital
Venous Thromboembolism, Venous Thrombosis
Mexican Multidisciplinary Registry of Patients With Venous Thromboembolic Disease
REMMITE, a retrospective and prospective registry with one-year follow-up, will provide valuable insights into the clinical diagnosis, management, treatment trends as well as related outcomes of three cohorts: DVT, DVT-PE, PE…
- Conditions
- Venous Thromboembolism, Venous Thrombosis, Pulmonary Embolism
- Trial name
- REMMITE (NCT02877251)
- Volunteers
- 500 people
- Sponsor
- Registro Mexicano Multidisciplinario De Pacientes Con Enfermedad Tromboembolica Venosa
Postoperative Cardiac Complication
VitamIn and oXygen Interventions and Cardiovascular Events
This study examines the risks and benefits of antioxidants and normal versus high inspiratory oxygen fraction during anaesthesia.
- Trial name
- VIXIE (NCT03494387)
- Testing
- Oxygen, Antioxidants
- Where
- 4 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Ischemic Stroke, Blood Pressure
Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients
Elevated blood pressure (BP) consists of a major public health concern especially in low and middle income countries. Besides being a highly prevalent condition, it is also a risk factor for several major cardiovascular events…
- Conditions
- Ischemic Stroke, Blood Pressure, Cognitive Impairment, Vascular Diseases
- Trial name
- OPTIMAL Stroke (NCT04036409)
- Testing
- Intensive Control of Systolic Blood Pressure (SBP), Standard control of Systolic Blood Pressure (SBP)
- Where
- 30 sites in Brazil
- Volunteers
- 4,368 people
- Sponsor
- Hospital Israelita Albert Einstein
Death, Myocardial Infarction
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events.
- Conditions
- Death, Myocardial Infarction, Cerebral Vascular Accident, Heart Failure Hospitalization
- Trial name
- TARGET-D (NCT02996721)
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Intermountain Health Care, Inc.
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
Non-obstructive Coronary Artery Disease
Endothelial Function Guided Therapy in Patients With Non-obstructive Coronary Artery Disease
The purpose of this study is to systematically evaluate the clinical application value of vascular endothelial function examination in patients with non-obstructive coronary artery disease.
- Trial name
- EndoFIND (NCT04013204)
- Testing
- Endothelial function guided therapy
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University
Dyslipidemia, High Risk Coronary Artery Disease
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
The primary objective was to evaluate the effect of treatment with evolocumab on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever…
- Trial name
- FORWARD (NCT04087915)
- Testing
- Evolocumab
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Cardiometabolic Diseases
REal-world Data of CARdiometabolic ProtEcTion
This study is a single-center, historical prospective cohort study including patients diagnosed with metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia.
- Trial name
- RED-CARPET (NCT07038083)
- Where
- China
- Volunteers
- 40,000 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT)…
- Trial name
- PRONOUNCE (NCT02663908)
- Testing
- Degarelix, Leuprolide
- Where
- 133 sites in United States, Canada and 10 more
- Volunteers
- 545 people
- Sponsor
- Ferring Pharmaceuticals
Thromboembolism, Arthroplasty, Replacement, Hip
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Open, prospective, uncontrolled, observational cohort study.
- Trial name
- NCT00967447
- Where
- 28 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
Coronary artery disease is the leading cause of death in USA. Contemporary cardiac care has substantially reduced mortality and morbidity in patients with severe coronary artery disease.
- Trial name
- NCT00868855
- Testing
- Bradykinin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vanderbilt University
Coronary Artery Disease, Type 2 Diabetes Mellitus
Comparison Between Pioglitazone and SES With type2 DM
Drug-eluting stents have been shown to decrease restenosis, but were associated with an increased rate of death, as compared with bare-metal stents.
- Trial name
- NCT00482183
- Testing
- Pioglitazone
- Volunteers
- 38 people
- Sponsor
- Showa University
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization.
- Trial name
- V-INTERVENTION (NCT06909565)
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 147 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Duke University